Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
53,514,204
-
Total 13F shares
-
16,606,568
-
Share change
-
-1,273,812
-
Total reported value
-
$48,328,000
-
Price per share
-
$2.91
-
Number of holders
-
28
-
Value change
-
-$3,750,524
-
Number of buys
-
6
-
Number of sells
-
12
Institutional Holders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) as of Q3 2022
As of 30 Sep 2022 Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) had 28 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 16,606,568 shares of stock of the company.
Largest 10 holders included Bain Capital Life Sciences Investors, LLC, Atlas Venture Life Science Advisors, LLC, Octagon Capital Advisors LP, FMR LLC, RiverVest Venture Management LLC, Rock Springs Capital Management LP, VANGUARD GROUP INC, AJU IB Investment Co., Ltd., Soleus Capital Management, L.P., and Artal Group S.A..
This table shows 28 institutional shareholders of the security as of 30 Sep 2022.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.